Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.
about
Atypical hemolytic uremic syndromeHemolytic uremic syndrome: new developments in pathogenesis and treatmentClinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaAlternative Complement Pathway Deregulation Is Correlated with Dengue SeverityProperdin: a tightly regulated critical inflammatory modulatorHaemolytic uraemic syndrome.The interaction between factor H and Von Willebrand factor.Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1Genetics and complement in atypical HUS.Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome.Complement activation in thrombotic microangiopathiesAssesment, treatment and prevention of atypical hemolytic uremic syndrome.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathyComprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Minor Role of Plasminogen in Complement Activation on Cell Surfaces.HUS and atypical HUS.Review: Complement and its regulatory proteins in kidney diseases.The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injuryThe alternative complement pathway revisited.Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).Cyclosporine induces endothelial cell release of complement-activating microparticles.Platelets and the complement cascade in atherosclerosis.Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation.The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment.Extracellular vesicles in renal disease.Abnormal platelet function in C3-deficient mice.Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab.The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells.Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation.
P2860
Q21202864-1C23267C-47D1-4051-A452-24E0F00B4F74Q24613517-E65A4211-A8D9-40EC-997C-3D9CE2156FFFQ26739894-9C2F8B14-DF3E-4534-AA00-E3B24AE02209Q27489374-C230AD86-917F-4D3F-AC68-476AB26A5BF2Q28069187-A0A3C4C5-631E-4E4E-BB66-3AD9D2A6D2F8Q30244707-13A38924-B5B2-4E05-97CB-27C4820C4978Q31133820-A0BED471-D251-499F-B2E6-A0FC5EB87C92Q33386199-2E5168BF-81F8-4B1F-9BD7-438851237C09Q33388175-D390A824-F997-4DCA-A572-E77E9613BFEFQ33389945-E23C14F9-B0FC-49BC-A4D7-29E7BDAC948CQ33395251-55A66D3B-4793-465C-B4DE-6511CFA30280Q33395774-68243F21-ACA9-4670-B230-5C10733AF675Q33403359-BF937F82-63C5-462E-9F38-0CD8F3A11AF8Q33403833-9A0C86AC-1A8C-43E3-9518-AEE76F488643Q33404158-413DB2D7-B023-4D7C-97EC-7CC268489655Q33405916-CDE4651B-4CE6-4E52-953F-6BDBA5968637Q33408733-4565C69F-44E7-4EE3-9D3A-39581ADDE016Q33409285-005A5858-9C47-4582-846A-5CB7016A0449Q33410276-FB5032C7-6E65-44F0-A1BA-DFBF89150C28Q33416830-4A73BACD-5AA2-4460-B762-AE41A280BA82Q33421669-522D8D57-8A23-49C9-962A-1EF619F32114Q33421861-E6D0E9C5-47AE-4AA6-A2D6-D08DFE15D116Q33428157-47A4609D-9538-4E6E-90EF-A06C58C797BFQ33441069-8AB3F3FB-C3BA-4815-968F-D5C272BDF703Q33647738-195C51FF-558A-4941-9958-E90428C50B7BQ33787385-179303F0-8057-4E98-982D-AB247E086860Q33976312-CF2C110D-74A3-4569-AB10-EB0C3859736FQ35891577-FCEF2D76-2FCF-43B3-B38F-5B4E29ECD6BCQ37141297-0591A8E4-6211-4636-865F-5663A1744943Q37200463-A5BD585D-BA06-4A4C-91A2-44D9D8E1A0C4Q37260192-486480E1-73C2-4A27-A540-239A1C01D6F5Q38382518-70B28D70-88C4-4806-A7F5-79F1DD8CFDE7Q38907049-4A46975F-2704-4084-A2F4-EC191FECD1FFQ38991010-4F82378F-9FCC-447C-BE89-1D3CD7DE5873Q39034874-F77E9038-CE3C-4F38-97C9-AE8633DCF66EQ39453434-B788A006-9F54-4ADF-82DF-870B1A8C0C7BQ40477168-EED611F1-3E0C-4C31-B5AC-60DADA171906Q40593336-496C5BBF-0F84-45A0-BD92-E8A1A37BA3CBQ40715358-22D522BC-77D3-43D3-A4DB-022D75EF2265Q47100595-3CC7669C-05A4-4E83-A6F7-0B8324BA4093
P2860
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Factor H dysfunction in patien ...... latelets and their activation.
@ast
Factor H dysfunction in patien ...... latelets and their activation.
@en
type
label
Factor H dysfunction in patien ...... latelets and their activation.
@ast
Factor H dysfunction in patien ...... latelets and their activation.
@en
prefLabel
Factor H dysfunction in patien ...... latelets and their activation.
@ast
Factor H dysfunction in patien ...... latelets and their activation.
@en
P2093
P50
P1433
P1476
Factor H dysfunction in patien ...... latelets and their activation.
@en
P2093
Alberto Gutierrez
Ann-Charlotte Kristoffersson
Anne-lie Ståhl
Fariba Vaziri-Sani
Karl-Henrik Gydell
Ortraud Beringer
Reem Raafat
P304
P356
10.1182/BLOOD-2007-08-106153
P407
P577
2008-02-11T00:00:00Z